-

03:45:38 AM

IMAB Stock News

IMAB - I-Mab

05/25/23 5:01 PM

Nasdaq : IMAB

clinical trial

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

-Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells.. -In newly diagnosed patients who were not eligib le for or declined chemotherapy treatment, 63% o f the patient s with CD73 High and PD-L1 TPS≥ 1% responded to the combination therapy while the response...

RHEA-AI

positive

05/01/23 8:00 AM

Nasdaq : IMAB

I-MAB Filed 2022 Annual Report on Form 20-F

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20- F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission on May 1, 2023..

RHEA-AI

neutral

04/26/23 9:16 AM

Nasdaq : IMAB

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of uliledlimab, the Company's proprietary and highly differentiated CD73 antibody, in combination...

RHEA-AI

neutral

04/25/23 1:46 AM

Nasdaq : IMAB

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to Tracon Tribunal confirmed the termination of both agreements...

RHEA-AI

neutral

04/24/23 9:00 AM

Nasdaq : IMAB

clinical trial

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational

RHEA-AI

neutral

04/11/23 6:00 AM

Nasdaq : IMAB

clinical trial

HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy

Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, today announced positive data from two Phase 2 studies of felzartamab, M-PLACE and NewPLACE. Felzartamab is an investigational monoclonal antibody designed to deplete CD38+ plasma cells, which are...

RHEA-AI

neutral

03/31/23 6:30 AM

Nasdaq : IMAB

earnings

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus Thirteen key clinical milestones achieved

RHEA-AI

neutral

03/20/23 8:00 AM

Nasdaq : IMAB

conferencesearnings

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results

RHEA-AI

neutral

03/07/23 8:02 AM

Nasdaq : IMAB

MSCI ESG Updated I-Mab to "A" Rating

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan

RHEA-AI

very positive

03/07/23 8:02 AM

Nasdaq : IMAB

MSCI ESG Updated I-Mab to "A" Rating

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI ESG, following MSCIESG's most recent annual review, and such rating outperforms 66% peers among global...

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

IMAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.i-mabbiopharma.com/en
Security nameI-Mab - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees378
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About I-Mab

I-Mab is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States.